| At MDRNA we are focused on realizing the potential of RNAi-based therapeutics through the development of a broad-based, state-of-the-art drug discovery platform built upon industry leading expertise in RNA chemistry and oligonucleotide delivery. We bring optimal value to our partners, shareholders and ultimately to patients through the discovery and development of RNAi-based therapeutics against human diseases including critical unmet medical needs in areas such as cancer, metabolic disorders and inflammation. More >>
|  | |
|
|
| Date | Title | | | 11/05/09 | MDRNA, Inc. to Hold Third Quarter 2009 Results Conference Call on Thursday, November 12, 2009 at 4:30 pm Eastern Time| BOTHELL, WA, Nov 05, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will host a
conference call with investors and security analysts on Thursday,
November 12, 2009, at 4:30 pm Eastern Time (1:30 pm Pacific Time) to
provide a business update and discuss financial results for the 3rd
quarter ended September 30, 2009. To participate in the live
conference call, U.S. residents should dial 866-543-6405 and
international callers should dial 617-213-8897. The p... |
|  | | 10/29/09 | MDRNA to Present Data on Tumor Reduction at Cancer Therapy Conference| Results Demonstrate Sustained Reduction in Liver and Bladder Tumor Growth via RNAi Mediated Knockdown of SurvivinBOTHELL, WA, Oct 29, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced the presentation of data related
to its RNAi oncology programs at the 24th Annual Meeting of the
International Society for Biological Therapy of Cancer, taking place
October 28-31, 2009 at the Gaylord National Hotel and Conve... |
| | | 10/22/09 | MDRNA to Present at the 8th Annual BIO Investor Forum| BOTHELL, WA, Oct 22, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today announced that J. Michael French, MDRNA's
President and Chief Executive Officer, will deliver a corporate
presentation and business update at the 8th Annual BIO Investor
Forum. The presentation will take place on Thursday, October 29,
2009 at 9:00am Pacific Time (12:00pm Eastern Time) at the Palace
Hotel in San Francisco, California.
To acces... |
| | | 10/12/09 | MDRNA Reports UsiRNA Reduces Tumor Growth In Vivo| Demonstrates RNAi-Mediated Knockdown of Previously "Non-Druggable" Targets in Liver and Bladder Cancers BOTHELL, WA, Oct 12, 2009 (MARKETWIRE via COMTEX) -- MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and
development company, today presented new in vivo data demonstrating
continued progress in the advancement of the Company's oncology
program. J. Michael French, President and CEO, reported that MDRNA's
UsiRNAs, delivered by the Company's DiLA2 platform, down-regulated... |
| |
|
|
| Primary IR Contact | John Woolford
Westwicke Partners
Phone: 443-213-0506
E-mail: ir@mdrnainc.com |
| | | Transfer Agent | American Stock Transfer & Trust Company
59 Maiden Lane
New York, NY 10038
Phone: 877-777-0800
Corporate Website: http://www.amstock.com
|
| | Legal | Pryor Cashman Sherman & Flynn LLP
410 Park Avenue
New York, NY 10022
Phone: (212) 421-4100
Corporate Website: http://www.pryorcashman.com
|
| | | Accountants | KPMG
3100 Two Union Square
801 Second Avenue
Seattle, WA 98104
Phone: 206-292-1500
Corporate Website: http://www.kpmgcampus.com
|
|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
|
